Financials data is unavailable for this security.
View more
Year on year Hangzhou Biotest Biotech Co Ltd 's revenues fell -76.75% from 1.90bn to 442.11m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 773.65m to 106.61m, a -86.22% decrease.
| Gross margin | 52.42% |
|---|---|
| Net profit margin | 19.64% |
| Operating margin | 24.12% |
| Return on assets | 4.01% |
|---|---|
| Return on equity | 4.35% |
| Return on investment | 4.23% |
More ▼
Cash flow in CNYView more
In 2023, Hangzhou Biotest Biotech Co Ltd did not generate a significant amount of cash. However, the company earned 131.38m from its operations for a Cash Flow Margin of 29.72%. In addition the company generated 74.36m cash from investing, though they paid out 249.19m more in financing than they received.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 22.27 |
|---|---|
| Tangible book value per share | 20.36 |
More ▼
Balance sheet in CNYView more
| Current ratio | 13.08 |
|---|---|
| Quick ratio | 12.53 |
| Total debt/total equity | 0.0003 |
|---|---|
| Total debt/total capital | 0.0003 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -63.64% and -86.16%, respectively. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 80.20% |
| EPS growth(5 years) | 41.45 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 638.50 |
More ▼
